Maple MOTS-C peptide research has emerged as one of the most compelling areas of mitochondrial biology in recent years. MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-C) is a 16-amino acid peptide encoded within the mitochondrial genome, making it part of a small but significant class of mitochondrial-derived peptides (MDPs) that appear to play key roles in cellular metabolism and energy homeostasis.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
What Is MOTS-C? Origin and Discovery
MOTS-C was first identified in 2015 by researchers at the University of Southern California’s Leonard Davis School of Gerontology. Published in Cell Metabolism, the discovery paper by Lee et al. (2015) demonstrated that this mitochondrial-encoded peptide could regulate metabolic homeostasis by targeting the folate cycle and de novo purine biosynthesis pathway. The study used both cell culture (HEK293 cells) and mouse models (C57BL/6J), with in vivo administration at 5 mg/kg showing significant effects on metabolic parameters (n=8 per group, p<0.01 for glucose tolerance improvements).
Unlike nuclear-encoded peptides, MOTS-C originates from the 12S rRNA gene within mitochondrial DNA. This makes it one of only a handful of known bioactive peptides encoded by the mitochondrial genome, alongside Humanin and SHLP1-6, which are also subjects of active investigation in aging and metabolic research.
MOTS-C Mechanism of Action: AMPK Pathway Activation
The primary mechanism through which MOTS-C exerts its metabolic effects involves activation of the AMP-activated protein kinase (AMPK) pathway. Research published in Cell Metabolism demonstrated that MOTS-C treatment activates AMPK in skeletal muscle tissue, with a 2.3-fold increase in phosphorylated AMPK (p-AMPK) levels compared to controls (Lee et al., 2015, p<0.001).
MOTS-C achieves this through a distinct upstream mechanism: inhibition of the folate-methionine cycle. Specifically, MOTS-C restricts 5-methyltetrahydrofolate (5-Me-THF) biosynthesis, which leads to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is a well-established endogenous AMPK activator. By increasing intracellular AICAR concentrations by approximately 3.5-fold (as measured by LC-MS/MS), MOTS-C effectively engages AMPK signaling without requiring direct kinase binding.
This mechanism is distinct from other AMPK activators like metformin or exercise, which primarily alter AMP:ATP ratios. MOTS-C instead modulates one-carbon metabolism upstream, positioning it as a unique metabolic regulator in preclinical research.
Metabolic Research Findings in Animal Models
Glucose Metabolism and Insulin Sensitivity
A 2015 study in Cell Metabolism (Lee et al.) reported that mice receiving MOTS-C (0.5 mg/kg/day IP for 7 days) showed a 32% reduction in fasting blood glucose compared to vehicle controls (n=8, p<0.01). Glucose tolerance tests (GTT) demonstrated a 40% improvement in area-under-the-curve (AUC) glucose clearance. These effects were observed in both normal chow-fed and high-fat diet (HFD) mice, though the magnitude was greater in the HFD cohort.
A follow-up study by Lee et al. (2019) published in the Journal of the American Geriatrics Society extended these findings to aged mice (24 months old, C57BL/6N strain). Aged mice treated with MOTS-C demonstrated improved insulin sensitivity as measured by homeostatic model assessment (HOMA-IR), with a 28% reduction compared to age-matched controls (n=10 per group, p<0.05).
Diet-Induced Obesity Models
In high-fat diet mouse models, MOTS-C administration prevented the expected weight gain trajectory. Reynolds et al. (2021) in Aging Cell showed that MOTS-C-treated HFD mice gained 35% less body mass over 8 weeks compared to HFD controls (n=12 per group, p<0.001), without affecting food intake. This suggested the peptide’s effects operated through increased energy expenditure rather than appetite suppression. Indirect calorimetry confirmed a 15% increase in oxygen consumption (VO2) in the MOTS-C group during the dark (active) cycle.
Exercise Mimetic Properties: Preclinical Evidence
One of the most intriguing aspects of MOTS-C research is its characterization as a potential exercise mimetic in preclinical models. A 2021 study published in Nature Communications by Reynolds et al. examined MOTS-C in the context of physical capacity in aged mice. Key findings included:
- Treadmill running capacity increased by 22% in 22-month-old mice receiving MOTS-C (5 mg/kg, 3x/week for 2 weeks) compared to age-matched controls (n=10, p<0.01)
- Skeletal muscle gene expression profiling (RNA-seq) revealed upregulation of 112 genes associated with mitochondrial biogenesis and oxidative phosphorylation
- PGC-1alpha protein expression increased 1.8-fold in gastrocnemius muscle (p<0.05)
- Circulating MOTS-C levels were shown to increase acutely following treadmill exercise in both young (3-month) and aged (22-month) mice
These findings positioned MOTS-C as an endogenous exercise-responsive factor, though researchers noted that the peptide alone did not fully replicate the comprehensive adaptive response to exercise training.
MOTS-C and Cellular Stress Response
Research has also investigated MOTS-C’s role in cellular stress adaptation. Kim et al. (2018) in Cell Reports demonstrated that under metabolic stress conditions, MOTS-C translocates to the cell nucleus, where it interacts with transcription factors involved in the antioxidant response. Specifically:
- Nuclear translocation of MOTS-C increased 4.2-fold under glucose restriction conditions in HEK293T cells
- ChIP-seq analysis revealed MOTS-C binding at promoter regions of ARE (antioxidant response element) genes
- Cells pre-treated with MOTS-C (10 micromolar, 24h) showed 45% less ROS accumulation under oxidative stress challenge (H2O2, 200 micromolar) compared to controls (p<0.001)
This nuclear translocation mechanism differentiates MOTS-C from many other metabolic peptides, which typically signal through cell-surface receptors.
Species Conservation and Human Correlative Data
MOTS-C is highly conserved across mammalian species. The human MOTS-C sequence differs from the mouse sequence by only one amino acid (position 14), suggesting strong evolutionary pressure to maintain its function. A 2019 cross-sectional study by D’Souza et al. published in Aging measured circulating MOTS-C levels in human plasma samples across age groups (n=116, ages 20-70). Key correlative findings included:
- Circulating MOTS-C levels declined approximately 11% per decade of age (p<0.01)
- Subjects in the highest MOTS-C quartile had 18% lower HOMA-IR scores compared to the lowest quartile (p<0.05)
- A specific mitochondrial DNA variant (m.1382A>C) in the MOTS-C coding region, prevalent in certain East Asian populations, was associated with higher type 2 diabetes risk (OR=1.47, 95% CI 1.12-1.93)
These correlative human data are notable but should not be interpreted as evidence for clinical efficacy. They do, however, support the biological relevance of MOTS-C as a metabolic signaling molecule and motivate further controlled research.
Key Research Findings Summary
- MOTS-C is a 16-amino acid mitochondrial-derived peptide that activates AMPK via inhibition of folate-methionine cycle intermediates, increasing AICAR levels approximately 3.5-fold
- In mouse models, MOTS-C administration improved glucose tolerance by 40% (AUC) and reduced fasting glucose by 32% (Lee et al., 2015, n=8, p<0.01)
- Diet-induced obesity models showed 35% less weight gain with MOTS-C treatment, attributed to 15% increased oxygen consumption (Reynolds et al., 2021, n=12, p<0.001)
- Aged mice (22 months) receiving MOTS-C demonstrated 22% increased treadmill capacity and 1.8-fold PGC-1alpha upregulation (Reynolds et al., 2021)
- MOTS-C translocates to the nucleus under metabolic stress, reducing ROS accumulation by 45% via antioxidant response element gene activation (Kim et al., 2018)
- Human correlative data shows circulating MOTS-C declines approximately 11% per decade, with lower levels associated with worse insulin sensitivity markers (D’Souza et al., 2019, n=116)
Research Peptide Quality and Verification
For researchers investigating MOTS-C, peptide purity is critical to experimental reproducibility. Impurities or degradation products can confound results, particularly in sensitive assays like LC-MS/MS metabolomics or phospho-AMPK western blots. Understanding how to interpret a Certificate of Analysis (COA) ensures that the peptide used in experiments meets the required purity threshold, typically 98% or higher as verified by HPLC analysis.
Maple Research Labs provides batch-specific third-party COA verification through Janoshik Analytical, an independent testing laboratory. This level of transparency is essential for researchers who need to verify the identity and purity of peptide reagents before use in controlled studies. For researchers sourcing peptides in Canada, domestic suppliers with documented purity verification reduce both shipping delays and the risk of customs-related degradation from extended transit times.
Future Directions in MOTS-C Research
Current MOTS-C research continues to expand along several axes. Ongoing preclinical work is investigating tissue-specific effects, particularly in cardiac muscle and brown adipose tissue. The mechanism of MOTS-C secretion from mitochondria and its regulation remain partially understood, representing an active area of basic science inquiry. Additionally, the interaction between MOTS-C and other mitochondrial-derived peptides (Humanin, SHLPs) may reveal coordinated mito-nuclear signaling networks relevant to metabolic research.
The convergence of MOTS-C’s metabolic effects with aging biology makes it a peptide of significant research interest. As analytical methods improve and more preclinical data accumulates, MOTS-C will likely remain a focal point in mitochondrial peptide research for years to come.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Browse our full selection of research peptides available with batch-specific COA verification from a trusted Canadian supplier.